Calliditas hits $90m jackpot as biotech IPO craze continues

Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease specialist at $467 million as the craze for biotech I

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

Calliditas pushing on with kidney disease drug after IPO suc...

Calliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it to bring a drug for a rare kidney disease to market.

Circassia a cautionary tale for UK biotech, says Grainger

The UK biotech company is putting its huge failure in allergy treatment behind it.  But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.

Are biotech IPOs back in fashion?

After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months as a series of companies announced plans to go public.

Cancer biotech BeyondSpring hit by weak IPO

Hoping for $100m, biotech raises under $3.5 million on stock market